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Stephanie J. Lee,1 Loretta A. Williams2Patient-reported outcomes (PROs) such as health-related quality of life, functional status, and symptom
burden have been recognized by the U.S. Food and Drug Administration (FDA) as legitimate measures of
clinical benefit for sponsors seeking drug approval. However, in practice, very few agents have been approved
based on these endpoints. Successful use of PROs in registration trials requires rigorous methods to over-
come numerous logistic and analytic barriers. Acute graft-versus-host disease (aGVHD) is associated with
high morbidity and mortality, and its prevention and treatment are the goals of many clinical trials in the
hematopoietic cell transplantation (HCT) research community. This article summarizes issues to be consid-
ered in the use of PROs as endpoints in aGVHD prevention and treatment trials.
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Clinical trialsINTRODUCTION
Patient-reported outcomes (PROs) refer to health-
related quality of life, functional status, and symptom
burden as perceived and reported by patients. For
example, symptoms are subjective phenomena re-
ported by patients that indicate a change in normal
functioning, sensation, or appearance because of dis-
ease [1]. Patient-reported measurement tools include
surveys, interviews, or patient diaries. These instru-
ments try to capture what people actually experience
with a treatment approach. Patient-reported measures
are complementary to physical exam findings and lab-
oratory testing, and are the primary source for much of
the clinician-reported symptom information in the
chart. For example, patient self-report is the most
direct means of capturing severity of nausea, pain,
and anorexia, and the only way to capture information
about fatigue and patient-perceived illness impact. In1Clinical Research Division, Fred Hutchinson Cancer
rch Center, Seattle, Washington; and 2Department of
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6/j.bbmt.2009.08.021recognition of this reality, the Common Terminology
Criteria for Adverse Events is undergoing revision to
include PRO items for symptom severity [2]. In sum-
mary, PROs reflect the patient’s personal experience
with disease and treatment.
Acute graft-versus-host disease (aGVHD) primar-
ily involves the skin as an erythematous rash, the liver
as a cholestatic or hepatitic process, or the gastrointes-
tinal (GI) system with nausea, vomiting, diarrhea, and
abdominal pain. Initial treatment for aGVHD in-
cludes corticosteroids, with other immunosuppressive
agents added as needed. If symptoms or side effects are
moderate to severe, patients may require hospitaliza-
tion for hydration, nutritional support, intravenous
delivery of medications, monitoring, treatment of in-
fections, and other supportive care. Both the aGVHD
disease process and the effects of treatments used to
prevent or treat GVHD may affect PROs.
In May 2009, the U.S. Food and Drug Adminis-
tration (FDA), in collaboration with several National
Institutes of Health (National Heart, Lung and Blood
Institute, National Cancer Institute, and National
Institute of Allergy and Infectious Diseases), the Cen-
ter for International Blood and Marrow Transplant
Research (CIBMTR), and the American Society of
Blood and Marrow Transplantation (ASBMT) con-
vened a meeting to discuss endpoints in aGVHD
trials, particularly with regard to the FDA approval
process. This article summarizes the discussion about
the role of PROs in trial design and interpretation
based on 4 questions posed by the conference
organizers.295
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TO BE PRIMARYOR SUPPORTIVE
ENDPOINTS?
The FDA requires evidence that treatments
provide ‘‘clinical benefit’’ defined functionally as
‘‘living longer or living better’’ before it will consider
drug approval. Draft guidance from the FDA states
that the amount and kind of PRO evidence to support
a labeling claim is the same as that required for any
other labeling claim [3]. Patient-reported endpoints
may refer to simple concepts, such as single symptoms
(eg, pain or nausea) or complex concepts, such as im-
provement in functioning (eg, working) or psychologic
state (eg, mood). Evidence of improvement in simple
PRO endpoints is not recognized for complex claims
such as improved health-related quality of life.
Although it may seem self-evident that decreasing nau-
sea or diarrhea would lead to better quality of life,
a sponsor needs to show actual effects on the claim
of improved quality of life. The draft guidance also
provides insights into the FDA’s opinion about several
other issues in PRO assessment and analysis such as
susceptibility to bias. For example, the guidance notes
that cognitive biases may affect patient responses so
PROs are considered unreliable in unblinded studies.
PRO instruments should capture current status and
actual functioning. Recall over more than a short pe-
riod of time or asking patients to estimate what they
may be able to accomplish is subject to substantial
bias. The guidance also provides practical advice for
sponsors designing trials. Because missing data often
compromise analytic plans, reasons for missing data
should be recorded during the trial so they can inform
the subsequent analysis.
Similar to the use of a new diagnostic tool, the
FDA needs to certify a PRO tool to ensure that it is suf-
ficiently validated to support the intended claim in the
target population. A previously validated instrument
that is modified in any way is considered a different in-
strument. If the study population differs substantially
from the population in which the instrument was
validated, the validationmay need to be repeated to en-
sure psychometric integrity. The FDA may choose to
review the instrument development and validation
process in detail. For example, the FDA may ask to
review the process of instrument creation including
patient interviews and focus group transcripts, cogni-
tive debriefing procedures, and readability tests. The
FDA may evaluate the text of the questions and the re-
sponse options offered to assess construct validity and
ensure absence of ceiling or floor effects. They will de-
termine whether the recall period is appropriate for the
study, and evaluate the instrument’s psychometric
properties including reliability, validity, sensitivity to
change, and clinically meaningful differences. Finally,
they will review the planned study procedures toensure accurate data capture, check instrument for-
matting, and review planned methods of data collec-
tion to make sure that results will be considered
accurate at the conclusion of the trial.WHAT CHALLENGES WILL BE
ENCOUNTERED, ESPECIALLY FOR aGVHD
TRIALS?
There are a number of general challenges to use of
PROs as endpoints in clinical trials. First, it is notori-
ously difficult to collect complete PRO data. PROs are
not available retrospectively or from other surrogate
sources. Collection of PROs requires active patient
cooperation, which is difficult although not impossible
to achieve when patients are very ill. For example,
Wang et al. [4] reported only 1.7% missing PRO
data in a group of 30 patients who completed the
M.D. Anderson Symptom Inventory (MDASI) twice
weekly during the first 30 inpatient days after alloge-
neic HCT. Outpatients and those obtaining care in
multiple health care settings offer different data collec-
tion challenges. Regardless of the setting of a clinical
trial, a data collection structure must be put in place
that is committed and able to collect all data as com-
pletely as possible. Many new technologies, such as in-
teractive voice response systems and Web-based
applications, are making collection of PRO data across
settings easier and more complete.
Frequency and timing of PRO assessments during
aGVHD trials may be critical in detecting a difference
in PRO endpoints. Symptoms from aGVHD may be-
gin several days before the diagnosis of disease and
worsen until several days after the initiation of effective
therapy [5]. Symptoms may then decline rapidly in re-
sponding patients after initiation of effective therapy,
so an assessment at 100 days or 6 months may miss im-
portant differences.
Different survey instruments are often required for
children or non-English-speaking patients, increasing
trial costs, and decreasing sample size, because often
these patients are analyzed as separate subsets. Perhaps
the greatest challenge is the fact that PRO tools are
clearly intended for research, and currently, separate
mechanisms must be established for their collection.
Physicians cannot just order PRO measurement as
they can a clinical test, contributing to the perception
that these are ‘‘extra’’ tasks and expendable because
they often do not directly contribute to patient care.
Although low-cost data collection options such as tele-
phone and computer technology are being developed,
these are not widely used yet [6,7]. A notable exception
is the assessment of patient-reported pain severity,
which has become routine in hospitals and clinics since
being mandated by the Joint Commission on the Ac-
creditation of Healthcare Organizations in 2001 [8],
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such as fatigue and distress should also be possible
[9,10].
It is also challenging to analyze and interpret
PROs. Longitudinal statistical methods are often
used, but generate sometimes incomprehensible re-
sults. Missing data are a big problem. The fact that pa-
tient-reported data are subjective and not objective is
their great strength and weakness. In the context of
a trial intended for FDA submission, the fact that
PROs are open to bias, particularly in opened-label
studies, is a serious limitation. However, because the
FDA will not accept some of the most common
aGVHD trials designs (unblinded, phase II), sponsors
will have to increase the rigor of their designs which of-
fers the potential to measure unbiased PROs.
There are some special considerations when using
PROs in the context of aGVHD trials. First, some
aGVHD such as liver involvement is usually not
symptomatic. Second, many symptoms and signs
overlap with other common HCT toxicities. Al-
though this is also true for more ‘‘objective’’ measures
of aGVHD severity such as laboratory tests and diar-
rhea, the high background ‘‘noise’’ in PROs from
conditioning regimen toxicity, drug side effects, in-
fections, and other complications adds to the back-
ground of considerable intrinsic measurement
variability. Patients with aGVHD are often quite ill,
with multiple concurrent complications. Perhaps
this is why more work has been done looking at
PROs in chronic GVHD (cGVHD) than in aGVHD,
because patients are often more clinically stable fur-
ther out from HCT.IN WHAT CIRCUMSTANCES CAN SHORT-
TERM PROS OR HEALTH-RELATED QUALITY
OF LIFE (RATHER THAN RESPONSE OR
SURVIVAL) BE AN ENDPOINT FOR aGVHD
PREVENTION OR TREATMENT TRIALS?
To clinicians, it is clear that patients withmoderate
to severe aGVHD, especially GI GVHD, are misera-
ble. Yet, it is hard to recommend PROs as primary
endpoints for GVHD prevention trials because the
prophylactic agents currently available are not that ef-
fective, the change inGVHD rates targeted tends to be
small, and the background noise is often too great to
allow a difference in PROs to be detected. Thus, the
most appropriate role of PROs currently is likely to
be in treatment trials. We believe that although pro-
longed disease-free survival (DSF) is paramount, an
agent that offers similar GVHD control and survival
but decreases symptoms such as frequency of diarrhea
and pain intensity, decreases hospitalization days, or
decreases side effects from treatment, may provide
a compelling case for FDA approval.Improvement in PROs may or may not correlate
with objective response criteria because they may be
fundamentally measuring different aspects of aGVHD
or have differing sensitivities to change. For example,
amount of diarrhea may or may not correlate with
symptoms of anorexia, nausea, abdominal pain, and
need for hospitalization. Also, GVHD response
measures are categoric (percent body surface area,
bilirubin level, volume of diarrhea, overall grade).
Improvements within organ stages may not result in
changes to overall grade, but could be associated
with improvement in symptoms. Conversely, decreas-
ing diarrhea from 1700 cc per day to 1400 cc per day
may not be noticeable to patients but would be consid-
ered improvement in GVHD severity by objective
measures.ARE THERE ANY VALIDATED PROS OR
OTHER HEALTH-RELATED QUALITY-OF-LIFE
TOOLS THAT CAN BE USED FOR aGVHD
TRIALS, ANDWHAT DATA SUPPORT THEIR
VALIDATION?
Currently there are no validated instruments that
meet the FDA requirements for a patient-reported
instrument in GVHD studies intended to support
approval of a claim. Three instruments have been
used most frequently to assess patients with
aGVHD. The Medical Outcomes Study Short
Form 36 (SF-36) is a 36-item generic functional sta-
tus tool that has been used in many healthy and ill
populations. It takes approximately 6 minutes to
complete, and provides 8 subscales and 2 summary
scores [11,12]. The Functional Assessment of Cancer
Therapy (FACT)-bone marrow transplant (BMT)
survey contains 37 items and also takes 6 minutes
to complete. It provides 4 core subscales, 1 BMT
module score, and 1 summary score [13]. The
MDASI contains 13 symptom items and 6 interfer-
ence items. It takes 5 minutes to complete and pro-
vides 2 summary scores for symptom severity and
interference [14]. Figure 1 shows examples of items
from these 3 instruments.
There are no studies that directly compare these
3 instruments in patients with aGVHD. The MDASI
focuses on specific symptoms and measures maximal
symptom severity within the previous 24 hours.
Frequency and duration of symptoms per se are not
measured, although they may be reflected in the sec-
tion measuring aggregate impact of symptoms on
functioning. The FACT-BMT includes items refer-
ring to symptoms, functional impact, and ‘‘satisfac-
tion/bother/enjoyment’’ within each domain. The
most common version used in HCT asks respondents
to report about the previous week. The FACT-BMT
provides domain scores, but not symptom or symptom
Figure 1. Examples of items from the MOS-SF36 (Medical Outcomes Study Short-Form 36), FACT-BMT (Functional Assessment of Cancer Therapy-
Bone Marrow Transplant module), and MDASI (M.D. Anderson Symptom Inventory). See text for details.
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functional status instrument. The acute version, mea-
suring status over the previous week, is usually used
in HCT studies. Some questions on the SF36 can be
confusing for HCT patients to interpret. For example,
many questions refer to work or housework or normalsocial activities with family and friends, but HCT
patients have limitations on these activities by virtue
of undergoing transplantation or being hospitalized
independent of their current health.
Although these instruments are well validated in
general and used extensively in HCT populations,
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aGVHD are not well established. Studies evaluating
clinically meaningful differences and sensitivity to
change are particularly needed.WHAT DATA EXISTABOUT PATIENT-
REPORTED MEASURES IN AGVHD?
Several studies provide some insight into how
aGVHD does or does not affect patient-reported mea-
sures. The NHLBI T cell depletion trial enrolled 410
patients from 1995 to 2000 who were randomized to ex
vivo T cell depletion or a cyclosporine (CsA) and
methotrexate (MTX) chemoprophylaxis regimen. Pa-
tient-reported measures including the FACT-BMT,
SF-36, and a depression scale were collected at base-
line and after HCT at day 100, 6 months, 1 year, and
3 years. There was a similar trajectory ofQOL changes
in both groups [15], although there was twice as much
grade III-IV aGVHD in the non-T cell depleted group
(37% versus 18%, P\ .0001) [16].
The group at the Dana-Farber Cancer Institute
studied 96 patients transplanted from 1999 to 2004
who provided a baseline Short Form 12 (SF-12) and
FACT-BMT with at least 1 follow-up at 6 or 12
months. Grade II-IV aGVHD was associated with
worse quality of life at 6 months, whereas cGVHD
was associated with worse quality of life at 1 year [17].
The group at M.D. Anderson has reported that
grade I-IV aGVHDwas associated with greater symp-
tom burden during days 22 to 100 after HCT than no
aGVHD. They studied 125 patients with a baseline
MDASI and between 6 and 20 follow-up assessments
[18].
Some ongoing aGVHD prevention and treatment
trials include PROs that will further help define the
role of these endpoints in GVHD trials. For example,
the recently completed, randomized, placebo-controlled
trial of mesenchymal stem cells for steroid-refractory
aGVHD treatment collected the FACT-BMT at treat-
ment days 0, 30, 100, and 180 (N5 280). A randomized,
placebo-controlled trial of oral beclomethasone dipro-
prionate for initial treatment of GI GVHD (target
N 5 166) will collect the MDASI weekly from enroll-
ment through 80 days. In both these FDA registration
trials, PROs are designated ‘‘additional endpoints.’’
The upcoming Clinical Trials Network Protocol 0802,
a randomized placebo-controlled trial of prednisone ver-
sus prednisone and mycophenolate mofetil (N 5 372)
will collect the MDASI prior to randomization and at
day 56 when the primary endpoint of GVHD response
is assessed. Results of the PRO analyses from these trials
are eagerly awaited.
Future studies should test whether patient-re-
ported measures can predict survival as well as
objective measures of aGVHD response.SUMMARY
Based on past work and the FDA’s currently stated
position, our opinion is that very narrow PRO claims
could be sought in GVHD treatment trials, with the
focus on symptoms rather than composite endpoints
or broad claims. The field urgently needs a validated
patient-reported instrument that meets the FDA
requirement for validation rigor. If such an instrument
were to become available, experience with the instru-
ment in a phase II study is recommended to better
plan for the phase III trial design.
aGVHD is a common complication following allo-
geneic HCT. Treatments that improve patients’ expe-
rience with aGVHD either through prevention or
successful treatment should be considered for FDA ap-
proval. However, there are still daunting methodo-
logic barriers to proving, by FDA standards, that
a treatment improves symptoms or health-related
quality of life related to aGVHD.ACKNOWLEDGMENTS
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